Clinical trials: Rosuvastatin
Cystic Fibrosis
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with…
- Trial name
- NCT07349394
- Testing
- VNZ/TEZ/D-IVA, Rosuvastatin
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Cardiovascular Diseases (CVD), Drug Effect
Randomized Comparison of Morning Versus Bedtime Administration of Statins: A Cardiovascular Circadian Chronotherapy (C3) Trial
Statins inhibit hydroxy-methylglutaryl coenzyme A (HMG-CoA) reductase which catalyzes the rate-limiting step in cholesterol synthesis.
- Conditions
- Cardiovascular Diseases (CVD), Drug Effect, Atherosclerosis Cardiovascular Disease
- Trial name
- STATIN-C3 (NCT06856772)
- Testing
- Statin in the evening (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), Statin in the morning (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
- Where
- Denmark
- Volunteers
- 42,000 people
- Sponsor
- Tor Biering-Sørensen
Healthy
Clinical Trial to Investigate the Efficacy and Safety of DWJ1351
The purpose of this study is to compare the safety and pharmacokinetic characteristics of combination of amlodipine, olmesartan and rosuvastatin and DWJ1351 in healthy male volunteers
- Trial name
- NCT03753477
- Testing
- DWJ1351(FDC Amlodipine/Olmesartan/Rosuvastatin), Sevikar and Crestor
- Where
- South Korea
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Hypercholesteremia
Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease
The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography…
- Trial name
- NCT00329160
- Testing
- Rosuvastatin, HMG CoA inhibitor
- Where
- 27 sites in Japan
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
ST-segment Elevation Myocardial Infarction
Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients
STEMI is a serious type of coronary heart disease, which is a major cause of disability and death. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as…
- Trial name
- NCT05895123
- Testing
- Rosuvastatin 20 mg, Atorvastatin 40mg
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Damanhour University
Osteoporosis
A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.
The first purpose of this study is to determine if taking SB-751689 along with Rosuvastatin (CRESTOR) or Atorvastatin (LIPITOR) will change how Rosuvastatin or Atorvastatin are absorbed and eliminated from the body.
- Trial name
- NCT00388596
- Testing
- SB-751689
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Kidney Disease
The Canadian Prevention of Renal and Cardiovascular Endpoints Trial
Advanced kidney disease with it's associated heart and blood vessel problems are becoming more frequent. These problems markedly affect length and quality of life and cost a lot to treat.
- Trial name
- CanPrevent (NCT00231803)
- Testing
- Combined CKD and CVD Prevention, Cardiovascular Disease prevention, Treatment of Chronic Kidney Disease complications
- Where
- 5 sites in Canada
- Volunteers
- 474 people
- Sponsor
- Brendan Barrett
Coronary Artery Disease
Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity
Patients with coronary artery disease (CAD) are often treated with dual antiplatelet therapy (DAT), including aspirin and clopidogrel, to prevent from recurrent atherothrombotic events.
- Trial name
- PEARL (NCT01567774)
- Testing
- Atorvastatin, Rosuvastatin
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Metabolic Syndrome X
ROMEO (Rosuvastatin in Metabolic syndrOme)
The primary objective of this study is to compare the effect of rosuvastatin 10mg with atorvastatin 10mg after 6 weeks of treatment in the ratio of ApoB/ApoA1 in subjects with metabolic syndrome.
- Trial name
- NCT00395486
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 3 sites in South Korea
- Volunteers
- 258 people
- Sponsor
- AstraZeneca
Drug Interaction
Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport
This is a single center, open-label, fixed sequence Phase 1, drug-drug interaction (DDI) study in healthy subjects.
- Trial name
- NCT05334108
- Testing
- Ecopipam, Cohort 1 Probe Substrate Cocktail, Cohort 2 Probe Substrate
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Emalex Biosciences Inc.
Dyslipidemia
Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe
The purpose of this study is to compare the pharmacokinetics of NVP-1205 and coadministration of rosuvastatin and ezetimibe.
- Trial name
- NVP-1205 (NCT02029625)
- Testing
- NVP-1205, rosuvastatin and ezetimibe
- Where
- South Korea
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- NVP Healthcare
ST Elevation Myocardial Infarction
Effect of Statin Preloading in STEMI in Improving PCI Outcomes
To compare the effect of a single high dose of atorvastatin versus rosuvastatin preloading on microvascular coronary perfusion as determined by CTFC in patients with ST-segment elevation myocardial infarction (STEMI) undergoing…
- Trial name
- NCT04974814
- Testing
- Rosuvastatin 40mg, Atorvastatin 80mg, Control Test
- Where
- Egypt
- Volunteers
- 99 people
- Sponsor
- Beni-Suef University
Acute Respiratory Distress Syndrome
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome
Platform adaptive embedded trial for acute respiratory distress syndrome (PETARDS) is a randomized, embedded, multifactorial, adaptive platform trial for ARDS.
- Trial name
- PETARDS (NCT05658692)
- Testing
- protective ventilation, prone position ventilation, glucocorticoid therapy
- Where
- 11 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Heart Failure
GISSI-HF- Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic CHF
INTRODUCTION While pharmacological treatments specifically targeted to the cardio-circulatory system have been largely investigated, scanty controlled data are available concerning the role of dietary and metabolic approaches in…
- Trial name
- NCT00336336
- Testing
- n-3 PUFA, Rosuvastatin
- Where
- 337 sites in Italy, Switzerland
- Volunteers
- 6,975 people
- Sponsor
- Gruppo di Ricerca GISSI
Hypercholesterolemia
Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy with or without other lipid-modifying therapy (LMT)…
- Trial name
- NCT02289963
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 27 sites in South Korea, Taiwan
- Volunteers
- 199 people
- Sponsor
- Sanofi
Hypercholesterolemia
Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal
The purpose of this study is to determine the efficacy of Crestor in high risk patients switched from higher doses of other statins in obtaining the new European Atherosclerosis Society (EAS) low-density lipoprotein cholesterol…
- Trial name
- NCT00240344
- Where
- 75 sites in Netherlands
- Volunteers
- 2,650 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2, Hypercholesterolemia
Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)
Objective: To investigate the effect of 5 weeks dapagliflozin 10 mg once daily treatment on glucose and lipid fluxes in patients with type 2 diabetes. Study design: Single center single arm (mechanistic) intervention trial.
- Trial name
- DICE (NCT03074630)
- Testing
- Dapagliflozin, Rosuvastatin
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Amsterdam UMC, location VUmc
Rheumatoid Arthritis
Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants
The primary objective of this study is to evaluate the effect of filgotinib on a mixed organic anion transporting polypeptide/cytochrome P450 3A (OATP/CYP3A), OATP/ breast cancer resistance protein (BCRP), and OATP substrates…
- Trial name
- NCT04608344
- Testing
- Atorvastatin, Pravastatin, Rosuvastatin
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Dyslipidemias
To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors
A multicenter, double-blind, parallel-group, active-controlled, dose-ranging study to assess the safety and efficacy of the novel cholesteryl ester transfer protein (CETP) inhibitor CKD-519 in combination with atorvastatin or…
- Trial name
- NCT02977065
- Testing
- Atorvastatin 20mg, Atorvastatin 20 mg + CKD-519 50 mg, Atorvastatin 20 mg + CKD-519 100 mg
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Chong Kun Dang Pharmaceutical
HIV-1 Infection
Rosuvastatin to Decrease Residual Immune Activation in HIV Infection
Participating countries: France Objectives Principal objective To evaluate, in HIV-1 infected patients receiving effective antiretroviral therapy, the effect of the addition of Rosuvastatin (dose of 20mg/day) for 3 months, on CD8…
- Trial name
- CESAR (NCT01874743)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba